RECRUITING Phase 2 / Phase 3 ClinicalTrials.gov

Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)

Sponsor: Johns Hopkins University • ClinicalTrials.gov ID: NCT07016321

Registry updated: 2026-10-13

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are: 1. Does emetine reduce 28-day mortality or progression to severe dengue (severe plasma leakage, severe bleeding, or severe organ involvement)? 2. What are the safety outcomes of emetine, including serious adverse events and toxicities? Participants will be asked to: 1. Take either 6mg emetine, 12mg emetine, or a placebo pill for 7 consecutive days as part of the treatment regimen. 2. Have blood samples taken for at least 5 days to monitor viral load, inflammatory markers, and safety parameters. 3. Be monitored by healthcare staff for daily vital signs and symptoms for clinical assessments for 28 days.

Interventions

Emetine Hydrochloride 6mg (Drug)
To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic dengue patients.
Placebo (Drug)
Participant take a placebo for 10 consecutive days.
Emetine Hydrochloride 12mg (Drug)
To administer Emetine Hydrochloride 12mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic dengue patients.

Eligibility criteria

Inclusion Criteria: 1. Age 18 to 65 years 2. Admitted to the hospital 3. Laboratory-confirmed infection with dengue virus within the last 5 days and preferably within the last 3 days. Testing for dengue virus using positive Nonstructural protein 1(NS1) strip assay or reverse-transcriptase polymerase chain reaction (RT-PCR) 4. Having two or more clinical symptoms (fever, headache, retro-orbital pain, myalgia, arthralgia, rash, hemorrhagic manifestations, or leucopenia, gastrointestinal symptoms) with the onset of fever within 72 hours of presentation, and 5. Able to provide voluntary informed consent and comply with all study procedures and visits. Exclusion Criteria: 1. Age ≥65 years 2. Pregnant or breastfeeding 3. Current or recent use of the study drug 4. Known allergy to study drug 5. Current or planned participation in another pharmacological interventional trial in the next 10 days 6. Participants with known past history of dengue infection 7. Participants on aspirin, anticoagulants, or with other conditions that might increase the risk of bleeding 8. Participants on immunosuppressive agents, including long-term steroids 9. Severe dengue as defined by the WHO 2009 revised case classification. 10. Individuals with long-term immunosuppressive agents such as anti-cancer chemotherapy or radiation therapy within the past 6 months, or those on systemic corticosteroid therapy 11. History of prior vaccination against dengue fever within one year. 12. Patients who have recently used ayurvedic or herbal medications for dengue or any other conditions in the last 7 days (eg, Papaya leaf extract)

Conditions

Dengue

Locations

Johns Hopkins University, Division of Infectious Disease — Baltimore, Maryland, United States
Bharatpur Hospital — Bharatpur-10, Chitwan, Nepal

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment